Antisense oligonucleotides and phospholipid vesicles containing said oligonucleotides for use in the treatment of psoriasis-induced itch - Patent Application 20070233334

Antisense oligonucleotides targeting miR-203b-3p microRNA provide a safe and effective treatment for psoriasis-induced itch, addressing the limitations of current therapies by inhibiting the microRNA responsible for itch in psoriasis.

JP2024541722APending Publication Date: 2024-11-11FLONEXT SRL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024529768
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-25
Filing Date
2022-11-23
Publication Date
2024-11-11

AI Technical Summary

Technical Problem

Current treatments for psoriasis-induced itch are ineffective and often cause severe side effects, lacking safe and effective options for managing this chronic symptom.

Method used

Administration of antisense oligonucleotides complementary to the miR-203b-3p microRNA sequence, which inhibits the activity of this microRNA responsible for itch in psoriasis, is used to develop a therapy that alleviates psoriasis-induced itch without significant side effects.

Benefits of technology

The therapy effectively reduces psoriasis-induced itch by inhibiting miR-203b-3p microRNA, providing a safe and effective treatment option for various types of psoriasis, including plaque psoriasis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541722000001_ABST
    Figure 2024541722000001_ABST
Patent Text Reader

Abstract

The present invention relates to the use of oligonucleotides complementary to the sequence of human miR-203b-3p microRNA in the treatment of psoriasis-induced itch. The present invention also relates to phospholipid vesicles comprising said oligonucleotides and the use of said phospholipid vesicles for the prevention and / or treatment of psoriasis-induced itch.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the use of oligonucleotides complementary to the sequence of human microRNA miR-203b-3p in the treatment of psoriasis-induced itching. The present invention also refers to phospholipid vesicles comprising said oligonucleotides and the use of said phospholipid vesicles for the treatment of psoriasis-induced itching. [Background technology]

[0002] Psoriasis is a chronic inflammatory skin disease that results from hyperproliferation of epidermal keratinocytes.

[0003] The most common form of psoriasis is plaque psoriasis (about 80% of forms of psoriasis), which is characterized by the formation of bright red plaques covered with white scales, most often, but not exclusively, located on the extensor surfaces of the hands and feet. In addition to plaque psoriasis, other forms of psoriasis include pustular psoriasis, guttate psoriasis, inverse psoriasis, and erythrodermic psoriasis.

[0004] Pustular psoriasis is distinguished from all other forms of psoriasis by the occurrence of yellowish pustules with purulent contents. Pustular psoriasis is also accompanied by fever, malaise, paresthesias, and a burning sensation.

[0005] Guttate psoriasis is characterized by a pink to red rash that is not covered with white scales.

[0006] With respect to inverse psoriasis, this causes large, pink, erythematous lesions which, in the most severe cases, may be complicated by the formation of relatively deep fissures or fissures that cause pain and may also bleed.

[0007] The most severe form of psoriasis, which is fortunately relatively rare, is erythrodermic psoriasis.Erythrodermic psoriasis is characterized by the presence of red spots that affect more than 90% of the body surface, and erythrodermic psoriasis is also accompanied by other important symptoms such as chills, cold sensation, itching and burning, general malaise, increased heart rate, asthenia, fever, swollen lymph nodes, and muscle and joint pain.This form of psoriasis is particularly disruptive to patients' daily life and often requires hospitalization.

[0008] The treatment options available today are aimed at preventing the progression of the disease, not at treating the itch that is a hallmark symptom of psoriasis.

[0009] In particular, the therapeutic solutions offered consist of topical treatments, ultraviolet (UV) light phototherapy, immunosuppressants, and systemic treatments.

[0010] In particular, topical treatments are based on the application of corticosteroids, topical vitamin D3 analogues, calcineurin inhibitors and / or tazarotene to psoriatic lesions.

[0011] However, treatment with corticosteroids is not without the common side effects caused by corticosteroids (irritation, burning sensation, dry skin, depigmentation), therefore corticosteroids can only be used for short periods of time.

[0012] Treatment with analogues of calcineurin makes it possible to avoid the side effects of corticosteroids, but even today it is not clear whether calcineurin analogues may increase the risk of lymphoma and skin cancer.

[0013] Tazarotene, a retinoid that is less effective than corticosteroids, can be used as an adjuvant and not as monotherapy.

[0014] Another option available for the treatment of psoriasis is phototherapy (or UV phototherapy), which is commonly used in patients with diffuse psoriasis. Although the treatment is more controlled than topical therapy and can result in remission for many months, repeated treatment may increase the incidence of UV-induced skin cancer and melanoma.

[0015] Immunosuppressants (eg hydroxyurea, 6-thioguanine) cause very severe side effects, have a narrow safety margin and are therefore only used in severe, resistant cases of psoriasis.

[0016] Finally, systemic treatment can be performed with retinoids (e.g., acitretin) or immunomodulators (tumor necrosis factor-alpha (TNF-alpha) inhibitors, e.g., etanercept, adalimumab, infliximab, and golimumab). However, due to the potential teratogenicity and long-term retention of retinoids in the body, women undergoing acitretin therapy should not be pregnant and should not become pregnant for at least two years after the end of treatment.

[0017] Furthermore, with regard to the immunomodulatory agents mentioned above, their safety profile is still under investigation. Indeed, inhibition of the TNF-alpha molecule can cause severe side effects, since the molecule is expressed in several organs and tissues.

[0018] Therefore, from a biological point of view, it may be useful to identify psoriasis-specific biomarkers that, if inhibited, would not cause severe side effects.

[0019] The lack of drugs without side effects on the one hand and, on the other hand, the known presence of symptoms that chronically torment patients with psoriasis, in particular itch, have prompted the search for new solutions to treat psoriasis.

[0020] Therefore, there is a clear need to provide preparations that can prevent and / or treat the symptoms of psoriasis, especially itch, without causing side effects. Summary of the Invention

[0021] The applicant has addressed the problem of providing a new therapy for the treatment of psoriasis, and in particular psoriasis-induced itch, that does not suffer from the drawbacks and side effects of current therapies.

[0022] The applicant has surprisingly found that a new therapy based on the administration of antisense oligonucleotides complementary to the miR-203b-3p microRNA sequence is particularly useful in treating psoriasis-induced itch.

[0023] In the present invention, the term "antisense oligonucleotide" refers to a small single-stranded DNA or RNA molecule that is complementary to a determined sequence. The sequence to which the antisense oligonucleotide binds is typically an mRNA molecule that can no longer be translated into protein by binding to a specific nucleotide sequence.

[0024] In particular, the antisense oligonucleotides for use according to the present invention are capable of binding to miR-203b-3p, a microRNA identified by the applicant as responsible for itch in psoriasis.

[0025] Binding of the antisense oligonucleotides described in the present invention to the miR-203b-3p microRNA inhibits the activity of the miR-203b-3p microRNA and thus the itch.

[0026] In order to provide an effective therapy for the treatment of psoriatic itch in humans, the applicants conducted studies on a mouse model of psoriasis.

[0027] The miR-203b-3p microRNA present in mice has a sequence that differs from the human miR-203b-3p microRNA by only one base (a cytosine instead of a uracil at the fifth position (SEQ ID NO: 1) as shown in Example 2). Applicants found that application of imiquimod (5%) to mouse skin induced lesions similar to those observed in human psoriasis, in particular resulting in epidermal thickening, skin redness, and the presence of plaques, responses collectively quantified in the PASI (Psoriasis Area Severity Index) (Figure 1B and Example 1). Treatment with imiquimod (5%) in mice also induced itch.

[0028] The applicant found that this itch was suppressed by subcutaneous administration of an oligonucleotide complementary to the mouse miR-203b-3p microRNA sequence (shown in Example 2 (SEQ ID NO: 2)).

[0029] As shown in the experimental section, inhibition of mouse miR-203b-3p by antisense oligonucleotides having a sequence (SEQ ID NO: 2) completely complementary to the sequence of the mouse miR-203b-3p microRNA can result in a reduction of itch in psoriatic lesions induced by treatment with imiquimod (5%) in mice.

[0030] This result paves the way for new therapies for the treatment of psoriasis-induced itch in humans. In particular, the applicant has found that an antisense oligonucleotide complementary to the miR-203b-3p microRNA sequence (SEQ ID NO: 3) present in humans, having a sequence (SEQ ID NO: 4) or a sequence with a percentage of identity to said sequence (SEQ ID NO: 4) at least equal to 70%, preferably at least 75%, even more preferably at least equal to 80%, can alleviate psoriasis-induced itch or, depending on the severity of the lesion, completely treat it. Thus, a first aspect of the present invention relates to an antisense oligonucleotide complementary to human miR-203b-3p microRNA (SEQ ID NO: 3) for use in the treatment of psoriasis-induced itch, having a sequence (SEQ ID NO: 4) or a sequence with a percentage of identity to said sequence (SEQ ID NO: 4) at least equal to 70%, preferably at least 75%, even more preferably at least equal to 80%.

[0031] In a preferred embodiment, the oligonucleotide according to the invention has at least 75% sequence identity to said sequence (SEQ ID NO: 4).

[0032] In a particularly preferred embodiment, the oligonucleotide according to the invention has at least 80% sequence identity to said sequence (SEQ ID NO: 4).

[0033] The antisense oligonucleotide for use according to the invention comprises a central 8-nucleotide sequence 5'-UUCUUAAC-3' which recognizes and inhibits the central part 5'-GUUAAGAA-3' of human miR-203b-3p. Indeed, said central 8-nucleotide sequence 5'-UUCUUAAC-3' is particularly relevant for pairing with and inhibiting human miR-203b-3p.

[0034] The antisense oligonucleotides described in this patent application can be advantageously used for the treatment of itch induced by all types of psoriasis, preferably for the treatment of itch induced by plaque psoriasis.

[0035] A second aspect of the invention relates to a phospholipid vesicle comprising at least one antisense oligonucleotide complementary to the human miR-203b-3p microRNA (SEQ ID NO: 3), said oligonucleotide having the sequence (SEQ ID NO: 4) or a sequence having a percentage of identity to said sequence (SEQ ID NO: 4) equal to at least 70%, preferably at least 75%, more preferably at least 80%.

[0036] A third aspect of the invention relates to a pharmaceutical composition comprising at least one phospholipid vesicle according to the second aspect of the invention. [Brief description of the drawings]

[0037] [Figure 1A] FIG. 1 shows experiments performed on a mouse model of psoriasis. [Figure 1B] FIG. 1 shows experiments performed on a mouse model of psoriasis. [Diagram 2] FIG. 1 shows experiments performed on a mouse model of psoriasis. [Diagram 3] 1 is a graph showing data obtained in an experiment on psoriasis model mice and control mice administered an oligonucleotide having a sequence completely complementary to the central portion of mouse miR-203b-3p microRNA. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0038] The present invention relates to the use of oligonucleotides complementary to the human miR-203b-3p microRNA sequence for the treatment of psoriasis-induced itch. Indeed, it has been observed that miR-203b-3p is the main cause of psoriasis-induced itch.

[0039] MicroRNAs are endogenous small, single-stranded non-coding RNA molecules that are approximately 20-22 nucleotides in length and act primarily in regulating gene expression at the transcriptional and post-transcriptional levels. In particular, microRNAs induce gene silencing by overlapping with complementary sequences present in messenger RNA (mRNA) molecules. Such binding results in the prevention of the translation of the microRNA's mRNA target into a protein or the degradation of said mRNA target by the microRNA target.

[0040] MicroRNAs can act by destabilizing mRNA molecules by cleaving them, shortening their poly(A) tails, or by reducing the translation efficiency of target mRNAs. The applicant has surprisingly discovered a new function for miR-203b-3p microRNA. Indeed, it has been observed in recent years that microRNAs not only function in post-transcriptional regulation of gene expression, but also act as ligands that are actively involved in cell lifespan.

[0041] The applicant advantageously performed experiments on a mouse model of psoriasis to evaluate the efficacy of antisense oligonucleotides directed to mouse miR-203b-3p microRNA in treating psoriasis-induced itch (see Experimental Section). In particular, a sequence (SEQ ID NO: 2) complementary to mouse miR-203b-3p was obtained from the sequence (SEQ ID NO: 1) of mouse miR-203b-3p microRNA, and the efficacy of this sequence (SEQ ID NO: 2) in reducing itch in a mouse model of psoriasis was observed.

[0042] The sequence of the mouse miR-203b-3p microRNA (SEQ ID NO:1) and the sequence of the oligonucleotide complementary to the mouse miR-203b-3p microRNA (SEQ ID NO:2) are depicted below: Sequence of mouse miR-203b-3p microRNA (SEQ ID NO:1) 5'-UUG AAC UGU CAAGAA CCA CUG G-3' Sequence of oligonucleotide complementary to mouse miR-203b-3p microRNA (SEQ ID NO:2) 5'-CCA GUG GUU CUUGAC AGU UCA A-3'

[0043] The applicant has surprisingly found that a new therapy based on the administration of antisense oligonucleotides complementary to the human miR-203b-3p microRNA sequence is useful in treating psoriasis-induced itch, particularly in subjects suffering from psoriasis.

[0044] Thus, a first aspect of the invention relates to an antisense oligonucleotide for use in the treatment of psoriasis induced itch, complementary to the human miR-203b-3p microRNA (SEQ ID NO: 3), having the sequence (SEQ ID NO: 4) or a sequence having a percentage of identity to said sequence (SEQ ID NO: 4) equal to at least 70%, preferably at least 75%, more preferably at least 80%.

[0045] In the present invention, the term "identity" means sequence identity, ie the degree of exact match (taking into account gaps) between two aligned oligonucleotide sequences.

[0046] An antisense oligonucleotide sequence for use according to the present invention is shown below and is represented with an identifier (SEQ ID NO:4). Sequence of an antisense oligonucleotide complementary to human miR-203b-3p microRNA (SEQ ID NO: 4) [ka]

[0047] The antisense oligonucleotides for use according to the present invention are capable of pairing with the human miR-203b-3p microRNA and inhibiting its action.

[0048] In particular, the human miR-203b-3p microRNA is a microRNA having the sequence shown below and represented in the present invention with an identifier (SEQ ID NO: 3). Sequence of human miR-203b-3p microRNA - (SEQ ID NO:3) [ka]

[0049] miR-203b-3p is a microRNA that is highly expressed at the skin level, and is a result related to the mechanism of skin morphogenesis. In fact, at the embryonic stage, this microRNA has been shown to be highly expressed in cells of the suprabasal layer of the epidermis and to be related to the regulation of the proliferation and differentiation mechanisms of epidermal cells (Sand et al., MicroRNAs and the skin: tiny players in the body's largest organ, J Dermatol Sci, 2009 53:169-75;).

[0050] The antisense oligonucleotide for use according to the invention is preferably composed of 23 nucleotides and has a sequence that is completely complementary to the sequence of the human miR-203b-3p microRNA (SEQ ID NO: 4) or has a percentage of identity to said sequence (SEQ ID NO: 4) equal to at least 70%, preferably at least 75%, more preferably at least 80%.

[0051] (SEQ ID NO: 4) is a sequence that is completely complementary to the human miR-203b-3p microRNA sequence (SEQ ID NO: 3).

[0052] In a particularly preferred embodiment, the antisense oligonucleotide comprises a central 8-nucleotide sequence 5'-UUCUUAAC-3', which is complementary to the central part of the human miR-203b-3p microRNA having the sequence 5'-GUUAAGAA-3'. In particular, the first uracil (U) of the central sequence UUCUUAAC corresponds to the base of the 9th nucleotide, and the last cytosine (C) of the central sequence corresponds to the base of the 16th nucleotide in the oligonucleotide for use according to the invention. Thus, the central sequence spans from the 9th nucleotide to the 16th nucleotide in the 23-nucleotide oligonucleotide for use according to the invention.

[0053] (SEQ ID NO: 4) contains a central sequence of 8 nucleotides 5'-UUCUUAAC-3', designated CORE sequence inhibitor. The central sequence, or CORE sequence inhibitor, is the central sequence of (SEQ ID NO: 4) of the oligonucleotide for use according to the invention, shown above in underlined and bold.

[0054] The central sequence, or CORE sequence, inhibitors can pair with and inhibit the central portion of the human miR-203b-3p microRNA, which is the CORE sequence of the human miR-203b-3p microRNA and has the sequence 5'-GUUAAGAA-3'.

[0055] The central portion of the human miR-203b-3p microRNA is underlined and bolded throughout the human miR-203b-3p microRNA sequence (SEQ ID NO:3). [ka]

[0056] According to the invention, antisense oligonucleotides having a sequence with a percentage of identity equal to at least 70%, preferably at least 75%, more preferably at least 80% to the sequence (SEQ ID NO: 4) are capable of reducing the itch induced by psoriasis. It is essential that the antisense oligonucleotides for use according to the invention recognize the central part of the human miR-203b-3p microRNA.

[0057] Thus, oligonucleotides for use according to the invention having a sequence with a percentage of identity equal to at least 70%, preferably at least 75%, more preferably at least 80% to the sequence (SEQ ID NO: 4) containing the central sequence 5'-UUCUUAAC-3' are capable of relieving psoriasis-induced itch.

[0058] An antisense oligonucleotide having a percentage of identity at least equal to 70% to the oligonucleotide (SEQ ID NO: 4) for use according to the present invention has the following sequence: 5'-ACA ACU UG UUCU UAA C AU GUC CA-3' (SEQ ID NO: 5) 5'-UCA CGU AC UUCU UAA C AU UUA CA-3' (SEQ ID NO: 6) 5'-AUG ACU GG UUCU UAA C AG UAG UA-3' (SEQ ID NO: 7) 5'-AGC UCA GG UUCU UAA C AG UUC AA-3' (SEQ ID NO: 8) 5'-UUA AGU GG UUCU UAA C AG CUA CA-3' (SEQ ID NO: 9) 5'-UGC UGA GG UUCU UAA C AG ACC AA-3' (SEQ ID NO: 10) 5'-UCA AAC GG UUCU UAA C AG UUC AA-3' (SEQ ID NO: 11) 5'-UCC CGU GG UUCU UAA C AG CUC GA-3' (SEQ ID NO: 12) 5'-UGC AGC GG UUCU UAA C AG UUA AA-3' (SEQ ID NO: 13) The nucleic acid may have a sequence selected from:

[0059] The sequences (SEQ ID NO:5) to (SEQ ID NO:7) have seven base differences with respect to the antisense oligonucleotide sequence (SEQ ID NO:4) that is completely complementary to human miR-203b-3p microRNA (SEQ ID NO:3).

[0060] In the present invention, a sequence having 7 base differences relative to the sequence (SEQ ID NO:4) is intended to have 70% sequence identity to said sequence (SEQ ID NO:4).

[0061] The sequences (SEQ ID NO:8) to (SEQ ID NO:10) have five base differences with respect to the antisense oligonucleotide sequence (SEQ ID NO:4) that is completely complementary to human miR-203b-3p microRNA (SEQ ID NO:3).

[0062] In the present invention, a sequence having 5 base differences relative to the sequence (SEQ ID NO:4) is intended to have 78% sequence identity to said sequence (SEQ ID NO:4).

[0063] The sequences (SEQ ID NO:11) to (SEQ ID NO:13) have three base differences from the antisense oligonucleotide sequence (SEQ ID NO:4) that is completely complementary to human miR-203b-3p microRNA (SEQ ID NO:3). In the present invention, the sequence having three base differences from the sequence (SEQ ID NO:4) is intended to have 87% sequence identity to the sequence (SEQ ID NO:4).

[0064] In one embodiment, the antisense oligonucleotide may have a sequence that has one or two base differences relative to the sequence of the antisense oligonucleotide (SEQ ID NO:4).

[0065] In the present invention, a sequence having one or two base differences relative to the sequence (SEQ ID NO:4) is intended to have greater than 90% sequence identity to said sequence (SEQ ID NO:4).

[0066] Furthermore, the sequences (SEQ ID NO:5) to (SEQ ID NO:13) all contain the central sequence 5'-UUCUUAAC-3' as defined in the present invention, which is underlined in the sequence.

[0067] Antisense oligonucleotides for use according to the present invention are capable of recognizing and binding to miR-203b-3p, but not to miR-203a-3p.

[0068] In a particularly preferred embodiment, the oligonucleotide for use according to the invention is an antagomir of the human miR-203b-3p microRNA.

[0069] In biotechnology, the term "antagomir" is intended to describe a class of chemically engineered oligonucleotides used to silence endogenous microRNAs of interest. In particular, antagomirs are synthetic RNAs that are perfectly complementary to the microRNA of interest, i.e., the microRNA that is intended to be inhibited. The structure of antagomirs has modifications that make them more resistant to degradation. Such modifications can be, for example, modifications of the nucleotide sugar, the nucleobase, or the internucleotide linkage.

[0070] In particular, the use according to the present invention relates to the treatment of itch induced by all types of psoriasis: plaque psoriasis, pustular psoriasis, guttate psoriasis, inverse psoriasis and erythrodermic psoriasis.Preferably, an antisense oligonucleotide complementary to human miR-203b-3p microRNA (SEQ ID NO: 3) and having the sequence (SEQ ID NO: 4) or a sequence having at least 70% identity percentage to said (SEQ ID NO: 4) can be used for the treatment of itch induced by plaque psoriasis.

[0071] By pairing with the human miR-203b-3p microRNA (SEQ ID NO: 3), the oligonucleotide for use according to the invention is capable of inhibiting the direct activity of the human miR-203b-3p microRNA in relation to the mechanism responsible for psoriasis-induced itch.

[0072] A second aspect of the invention is a formulation comprising an antisense oligonucleotide complementary to human miR-203b-3p microRNA. In particular, the second aspect of the invention is a phospholipid vesicle comprising at least one antisense oligonucleotide complementary to human miR-203b-3p microRNA (SEQ ID NO: 3), said oligonucleotide having the sequence (SEQ ID NO: 4) or a sequence having a percentage of identity to said sequence (SEQ ID NO: 4) equal to at least 70%, preferably at least 75%, more preferably at least 80%.

[0073] As described above, (SEQ ID NO: 4) is a sequence that is completely complementary to the human miR-203b-3p microRNA (SEQ ID NO: 3).

[0074] The phospholipid vesicles according to the present invention may comprise one or more of the following oligonucleotides having a sequence that is fully complementary to the human miR-203b-3p microRNA (SEQ ID NO: 4) or a sequence that has at least 70%, preferably at least 75%, more preferably at least 80% to the sequence (SEQ ID NO: 4).

[0075] In one embodiment, a vesicle according to the invention may comprise one or more of the oligonucleotides having the sequences (SEQ ID NO:5), (SEQ ID NO:6) and (SEQ ID NO:7).

[0076] In one embodiment, a vesicle according to the invention may comprise one or more of the oligonucleotides having the sequences (SEQ ID NO:8), (SEQ ID NO:9) and (SEQ ID NO:10).

[0077] In one embodiment, a vesicle according to the invention may comprise one or more of the oligonucleotides having the sequences (SEQ ID NO:11), (SEQ ID NO:12) and (SEQ ID NO:13).

[0078] In another embodiment, the phospholipid vesicles may comprise one or more of the oligonucleotides having the sequences (SEQ ID NO:5), (SEQ ID NO:6) and (SEQ ID NO:7), and / or one or more of the oligonucleotides having the sequences (SEQ ID NO:8), (SEQ ID NO:9) and (SEQ ID NO:10), and / or one or more of the oligonucleotides having the sequences (SEQ ID NO:11), (SEQ ID NO:12) and (SEQ ID NO:13).

[0079] In further embodiments, the phospholipid vesicles may comprise an antisense oligonucleotide (SEQ ID NO:4), and / or one or more of the oligonucleotides having the sequences (SEQ ID NO:5), (SEQ ID NO:6) and (SEQ ID NO:7), and / or one or more of the oligonucleotides having the sequences (SEQ ID NO:8), (SEQ ID NO:9) and (SEQ ID NO:10), and / or one or more of the oligonucleotides having the sequences (SEQ ID NO:11), (SEQ ID NO:12) and (SEQ ID NO:13).

[0080] The phospholipid vesicles according to the invention can be chosen from liposomes, phytosomes, micelles or mixtures thereof, preferably liposomes.

[0081] Liposomes are a widely utilized delivery system for the delivery of poorly absorbed or poorly soluble actives, including pharmacologically actives.

[0082] Due to the surfactant properties of the phospholipids that compose the liposomes, the liposomes "encapsulate" the active substance, in this case one or more oligonucleotides for the use according to the invention.

[0083] Advantageously, the components of the phospholipid layer of the liposomes are biocompatible, and therefore the liposomes do not cause adverse effects.

[0084] It is therefore clear that the formulation described in the present invention advantageously allows to deliver high concentrations of the above described antisense oligonucleotides, as a result of which said formulation can act on the target microRNA, i.e. human miR-203b-3p microRNA, and contribute to the reduction, if not complete elimination, of the itch induced by psoriasis.

[0085] In one embodiment, the phospholipid vesicles according to the invention are phytosomes.

[0086] Phytosomes are delivery systems structurally related to liposomes, prepared by binding individual components of herbal extracts to phosphatidylcholine.

[0087] Phytosomes differ from liposomes in that the active ingredient is contained entirely within the vesicular structure formed by phospholipids, in that the active ingredient is anchored to the polar head groups of phospholipids and becomes an integral part of the vesicle membrane.

[0088] In another embodiment, the phospholipid vesicles according to the invention are micelles.

[0089] Micelles are spherical particles in which the phospholipids are arranged with the polar heads facing outwards, i.e. towards the aqueous environment, and the tails facing towards the inside of the micelle. According to said embodiments, the micelles can be unilamellar micelles (single layer) or bilayer micelles (bilayer).

[0090] In a particularly preferred embodiment, the phospholipid vesicles are liposomes.

[0091] In particular, liposomes according to a preferred embodiment of the present invention have a size between 100 nm and 800 nm, preferably between 200 nm and 600 nm, even more preferably 400 nm.

[0092] Furthermore, said liposomes are preferably characterized by a polydispersity index between 0.2 and 0.4, preferably 0.3.

[0093] Polydispersity index is a measure of the heterogeneity of a sample based on size. Polydispersity can arise due to size distribution in the sample or due to aggregation or aggregation of the sample during isolation or analysis.

[0094] The phospholipid vesicles are preferably composed of corn lecithin, sunflower lecithin, soybean lecithin, and more preferably corn lecithin.

[0095] The phospholipid vesicles, preferably liposomes, according to the present invention can be used for the treatment of itch caused by plaque psoriasis, pustular psoriasis, guttate psoriasis, inverse psoriasis and erythrodermic psoriasis, preferably plaque psoriasis.In particular, said phospholipid vesicles can be used for external application to psoriasis lesions to achieve a reduction in itch or a complete disappearance of itch.

[0096] A third aspect of the invention relates to a pharmaceutical composition comprising one or more phospholipid vesicles as described in the second aspect of the invention and as described above.

[0097] In one embodiment, the pharmaceutical compositions according to the invention may comprise a mixture of liposomes, phytosomes and micelles containing one or more oligonucleotides for use according to the invention.

[0098] In one embodiment, the composition may comprise at least one phospholipid vesicle comprising at least one antisense oligonucleotide having the sequence (SEQ ID NO:4) and / or a sequence having a percentage identity to the sequence (SEQ ID NO:4) equal to at least 70%, preferably at least 75%, more preferably at least 80%.

[0099] According to the present invention, the composition may further comprise one or more pharma- ceutically suitable or pharma- ceutically acceptable excipients.

[0100] The expression "pharmaceutical acceptable" is intended to define, without any particular limitations, any substance that is suitable for the preparation of a pharmaceutical composition to be administered to an organism.

[0101] The expression "pharmaceutical suitable excipients" is intended to mean any solvents, diluents or other vehicles, dispersing or suspending aids, surfactants, isotonicity agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like.

[0102] Some examples of substances which may function as pharma- ceutically acceptable excipients include, but are not limited to, sugars such as lactose, glucose and sucrose; starches such as corn starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate, powdered gum tragacanth, malt, gelatin, talc, excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate, agar, buffers such as magnesium hydroxide and aluminum hydroxide, alginic acid, pyrogen-free water, isotonic salt solutions, ethyl alcohol and phosphate buffer solutions, other compatible and non-toxic lubricants such as sodium lauryl sulfate and magnesium stearate, colorants, release agents, coating agents, sweeteners, flavoring and perfuming agents, preservatives and antioxidants.

[0103] The pharmaceutical forms may also contain other traditional ingredients such as preservatives, stabilizers, surfactants, buffers, salts for adjusting the osmotic pressure, emulsifiers, sweeteners, colorants, flavors, and the like.

[0104] The pharmaceutical composition according to the third aspect of the present invention can be formulated for external administration, for example in the form of cream, powder or ointment.In another embodiment, the pharmaceutical composition has a formulation that is useful for application in the form of medicinal patch.Medicinal patch is a formulation for transdermal use, which is applied to the skin and releases a specified amount of drug in a controlled and constant manner.

[0105] In a preferred embodiment, the compositions of the present invention are formulated in the form of a cream.

[0106] Such compositions, preferably in the form of a cream, can be applied topically to one or more psoriasis lesions to achieve gradual relief of itching or complete cure of itching.Accordingly, the compositions according to the present invention can be used for topical treatment of psoriasis-induced itching, particularly plaque psoriasis, pustular psoriasis, guttate psoriasis, inverse psoriasis and erythrodermic psoriasis.

[0107] The present description further relates to a method of treatment of psoriasis-induced itch, comprising the topical application of at least one antisense oligonucleotide having the sequence (SEQ ID NO: 4) and / or a sequence having a percentage of identity to the sequence (SEQ ID NO: 4) equal to at least 70%, preferably at least 75%, more preferably at least 80%.

[0108] In particular, the method of treating psoriasis-induced itch comprises the topical application of one or more of the phospholipid vesicles described above, preferably in the form of a cream, to at least one psoriatic lesion of a subject suffering from psoriasis.

[0109] In one embodiment, the method of treatment may also include administration of drugs commonly used for the treatment of psoriasis.

[0110] Examples of such drugs are corticosteroids, topical vitamin D3 analogues, calcineurin inhibitors and / or tazarotene.

[0111] One or more of the above mentioned drugs may be administered together with the sequence (SEQ ID NO: 4) and / or at least one oligonucleotide having a sequence having a percentage of identity to the sequence (SEQ ID NO: 4) equal to at least 70%, preferably at least 75%, more preferably at least 80%.

[0112] One or more of the drugs conventionally used for the treatment of psoriasis, preferably selected from corticosteroids, topical vitamin D3 analogues, calcineurin inhibitors and / or tazarotene, may be administered before, after or simultaneously with the topical treatment with the antisense oligonucleotides as defined above, optionally encapsulated in phospholipid vesicles as defined above, or with the pharmaceutical composition according to the third aspect of the invention.

[0113] Thus, a combination of phospholipid vesicles according to the second aspect of the invention with corticosteroids, topical vitamin D3 analogues, calcineurin inhibitors and / or tazarotene for simultaneous, separate or sequential use in the treatment of psoriasis-induced itch may be particularly effective in determining complete healing of the targeted psoriatic lesions. EXAMPLES

[0114] A detailed description of the figures can be found in the Examples below. Example 1 – Mouse model of psoriasis Inhibition of mouse miR-203b-3p microRNA by antisense oligonucleotides with a sequence completely complementary to mouse miR-203b-3p microRNA was studied in a mouse model of psoriasis induced by topical (cutaneous) treatment with imiquimod (5%) for 6 consecutive days.

[0115] The above in vivo experiments were carried out in accordance with the guidelines provided by Italian law (DLgs26 / 2014) and European regulations (EU Directive 2010 / 63 / EU). The study was carried out after approval of the protocol by the Ministry of Health (research permit no. 511 / 2021-PR).

[0116] Male C57BL / 6J mice, aged 5-8 weeks and weighing 22-25 g, supplied by Charles River (Milan, Italy) were used for the experiments. A total of 24 mice were used to carry out the experiments described below. The animals were kept in a temperature- and humidity-controlled environment (12-h dark / light cycle, food and water available ad libitum). The experiments were carried out in a temperature-controlled room (20-22°C) between 8:00 am and 8:00 pm. At the end of the experiments, the animals were kept in a 20-22°C room temperature room for 12 h. 2 50% CO 2 Euthanasia was achieved by inhalation of a 50% mixture for 1 min.

[0117] The day before the experiment, the backs of mice (24) were shaved using an electric razor, and remaining hair was removed using depilatory cream.

[0118] The following day, mice (n=12) received a topical application of 62.5 mg of imiquimod cream (5%, Aldara, 3M Pharmaceuticals, UK) to the shaved area, corresponding to a daily dose of 3.125 mg of active compound. The doses used were those that resulted in reproducible skin inflammation with characteristics similar to those seen in psoriasis patients (specific cytokine expression patterns, histopathological changes and cellular infiltration) (Van der Fits et al., 2009 Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23 / IL-17 Axis J Immunol, 2009, 182(9)5836-5845.; Yoshiki, R. et al., 2014 IL-23 from Langerhans Cells Is Required for the Development of Imiquimod-Induced Psoriasis-Like Dermatitis by Induction of IL-17A-Producing γδ T Cells. J. Invest. Dermatol. 134, 1912-21).

[0119] Control animals (n=12) were treated with the imiquimod vehicle (control cream), which consisted of petrolatum cream.

[0120] Application of the cream was performed by two practitioners, one to hold the animal still while the other applied the cream using a cotton swab.

[0121] Imiquimod cream (5%) or control cream was applied daily to the shaved skin on the backs of mice for six consecutive days.

[0122] FIG. 1A shows a schematic of the treatment schedule for mice treated with imiquimod or with imiquimod vehicle (referred to as control mice).

[0123] Treatment with imiquimod cream caused psoriatic lesions in mice, as can be seen in Figure 1B, where it is possible to observe the PASI (Psoriasis Area Severity Index) scores detected for control and imiquimod-treated mice. Data are shown as mean ± SEM. * p<0.05 versus imiquimod vehicle (control), statistical analysis by Student's t test.

[0124] The PASI index is a dermatological index introduced in the late 1970s to monitor the effectiveness of treatments used for the treatment of psoriasis. In the assessment of the PASI score, several parameters are evaluated and given a score that varies from 0 (no psoriasis) to 72 (maximum, severe psoriasis). In this experiment, the following parameters were evaluated for the calculation of the PASI: appearance of erythema, scaling, and skin thickening. Each of these parameters was independently evaluated on a scale of 0 to 4: 0-none, 1-mild, 2-moderate, 3-marked, 4-maximum. A cumulative score (erythema + scaling + thickening) was used to measure the severity of inflammation (scale of 0 to 12). The scores of each mouse were averaged. In Figure 1B, it is possible to observe that the cumulative PASI score of the imiquimod-treated mice was 7.58 ± 1.43 on a scale of 0 to 12. It is therefore reasonable to conclude that the imiquimod treatment led to inflammation and typical psoriatic lesions. These mice are therefore a good model for the study of psoriasis and of treatments useful in treating the disease.

[0125] Example 2 - Use of an oligonucleotide with a sequence perfectly complementary to the mouse miR-203b-3p microRNA In particular, the applicant has found that an oligonucleotide having a sequence (sequence number 2) complementary to the sequence (sequence number 1) of mouse miR-203b-3p microRNA can pair with the complete sequence of mouse miR-203b-3p microRNA, inhibit its action, and prevent the ultimate development of itch.

[0126] The sequence of the mouse miR-203b-3p microRNA, represented with its identifier (SEQ ID NO:1), is shown below: Sequence of mouse miR-203b-3p microRNA (SEQ ID NO:1) [ka]

[0127] The sequence of the oligonucleotide complementary to the mouse miR-203b-3p microRNA (SEQ ID NO:1) is shown below along with its identifier (SEQ ID NO:2): Sequence of oligonucleotide complementary to mouse miR-203b-3p microRNA (SEQ ID NO:2) [ka]

[0128] In particular, the sequence (SEQ ID NO:2) is a 22 nucleotide sequence in mouse that is completely complementary to the sequence of mouse miR-203b-3p microRNA (SEQ ID NO:1).

[0129] Said oligonucleotide (SEQ ID NO: 2) was used to test the efficacy of inhibiting mouse miR-203b-3p microRNA and evaluate the effect of reducing psoriasis-induced itch in a mouse model of psoriasis, so that these results could be applied to humans.

[0130] (SEQ ID NO:2) is a sequence that is fully complementary to the mouse miR-203b-3p microRNA (SEQ ID NO:1). The human counterpart of the mouse sequence (SEQ ID NO:2), i.e., a sequence that is fully complementary to the human miR-203b-3p microRNA, is an oligonucleotide having the sequence (SEQ ID NO:4).

[0131] In particular, C57BL / 6J mice were treated with imiquimod (n=12) and control mice were treated with imiquimod vehicle (petrolatum cream) (n=12). Mice treated with either imiquimod or imiquimod vehicle were divided into two further experimental groups, of which 6 mice treated with imiquimod and 6 mice treated with imiquimod vehicle were treated with a sequence complementary to mouse miR-203b-3p microRNA (Integrated DNA Technologies IDT, Tema Ricerche) intradermally (1 nmol, 10 μl) in the neck of the mice daily for 6 consecutive days after imiquimod or imiquimod vehicle administration.

[0132] In addition, six mice treated with imiquimod and six mice treated with imiquimod vehicle were treated with inhibitor vehicle (a solution in which the complementary sequence was diluted, represented by a 0.9% solution of sodium chloride, NaCl).

[0133] Treatment with the complementary sequence (SEQ ID NO: 2) or vehicle was administered once daily from day 1 to day 6 of treatment with imiquimod or imiquimod vehicle.

[0134] On the 7th day, i.e. after administration of imiquimod cream (5%) or control cream and treatment with a sequence complementary to the mouse miR-203b-3p microRNA defined as an inhibitor (SEQ ID NO: 2) or inhibitor vehicle, animals were placed in a 30 cm x 30 cm arena and video recorded for 1 hour.

[0135] The videos were then viewed by a practitioner who counted the number of times the animals scratched with their hind paws at the sites where imiquimod cream (5%) or control cream had been applied following treatment with a sequence complementary to the mouse miR-203b-3p microRNA (SEQ ID NO: 2), defined as an inhibitor, or inhibitor vehicle.

[0136] Measurement of the number of times an animal scratches itself with its hind paw at the site of application of imiquimod cream (5%) or control cream after treatment with a sequence complementary to mouse miR-203b-3p microRNA (SEQ ID NO: 2) or its vehicle, defined as the number of scratches, is an index of the presence of itch.

[0137] In the abscissa of FIG. 2, the term "inhibitor" refers to treatment performed with an oligonucleotide (SEQ ID NO: 2) complementary to mouse miR-203b-3p microRNA, and the term "inhibitor vehicle" refers to treatment performed with a diluted solution of oligonucleotide complementary to mouse miR-203b-3p microRNA (represented by a 0.9% solution of sodium chloride, NaCl).

[0138] As can be seen in Figure 2, treatment with imiquimod (5%) induced a significant increase in the number of scratches relative to animals treated with a control cream. Treatment with a sequence complementary to the mouse miR-203b-3p microRNA was able to reduce the number of scratches at the site where imiquimod cream was applied (5%) in mice treated with imiquimod (5%) (psoriasis model mice).

[0139] This experiment shows that a sequence completely complementary to the mouse miR-203b-3p microRNA can reduce itch in a mouse model of psoriasis induced by imiquimod (5%).

[0140] Data are presented as mean±SEM. * p<0.05 vs. imiquimod vehicle (control); § p<0.05 vs. imiquimod / inhibitor vehicle. Statistical analysis by one-way analysis of variance (ANOVA) and Bonferroni test.

[0141] Example 3 - Use of an oligonucleotide with a sequence perfectly complementary to the central part of the mouse miR-203b-3p microRNA To determine the efficacy of the central sequence 5'-UUCUUAAC-3' of the antisense oligonucleotide for use in humans, studies were performed in mice by specifically testing an oligonucleotide complementary to the central portion of the mouse miR-203b-3p microRNA. The oligonucleotide was used to evaluate the efficacy of reducing psoriasis-induced itch in a mouse model of psoriasis, so that these results could be applied to humans.

[0142] Mouse miR-203b-3p microRNA central region (CORE sequence) 5'-GUCAAGAA-3' Complementary to 5'-UUCUUGAC-3' An antisense oligonucleotide having the sequence was obtained. In particular, the antisense oligonucleotide having the sequence 5'-UUCUUGAC-3' is an 8-nucleotide sequence in mouse that is completely complementary to the CORE sequence of mouse miR-203b-3p microRNA.

[0143] The antisense oligonucleotide used in this experiment has a sequence that is completely complementary to the central portion or CORE sequence of the mouse miR-203b-3p microRNA sequence (SEQ ID NO: 1) shown in Example 2.

[0144] The sequence 5'-UUCUUGAC-3' is the center sequence of the oligonucleotide (SEQ ID NO: 2) that is complementary to the center sequence of the mouse miR-203b-3p microRNA shown in Example 2, or the CORE sequence inhibitor.

[0145] For this experiment, C57BL / 6J mice were treated with imiquimod (n=12) and control mice were treated with imiquimod vehicle (petrolatum cream) (n=12). Mice treated with imiquimod or imiquimod vehicle were divided into two further experimental groups, of which 6 mice treated with imiquimod and 6 mice treated with imiquimod vehicle were treated with an antisense oligonucleotide (Integrated DNA Technologies IDT, Tema Ricerche) with the sequence 5'-UUCUUGAC-3' complementary to the central part or CORE sequence of mouse miR-203b-3p microRNA (referred to as "CORE seq inhibitor" in Figure 3) administered intradermally (1 nmol, 10 μl) to the neck of the mice daily for 6 consecutive days after administration of imiquimod (5%) or imiquimod vehicle.

[0146] In addition, six mice treated with imiquimod (5%) and six mice treated with imiquimod vehicle were treated with a diluted solution of antisense oligonucleotide vehicle, i.e., a sequence complementary to the central or CORE sequence, represented by a 0.9% solution of sodium chloride, NaCl (referred to as "CORE seq inhibitor vehicle" in Figure 3).

[0147] Treatment with antisense oligonucleotides and vehicle was given once daily from day 1 to day 6 of treatment with imiquimod (5%) or imiquimod vehicle.

[0148] On the 7th day, i.e., after administration of imiquimod cream (5%) or control cream and treatment with an oligonucleotide having a sequence complementary to the central portion of the mouse miR-203b-3p microRNA or vehicle, the animals were placed in a 30 cm × 30 cm arena and video recorded for 1 hour.

[0149] The video was then viewed by a practitioner who counted the number of times the animals scratched with their hind paws at the site where imiquimod cream (5%) or control cream had been applied after treatment with the antisense oligonucleotides or vehicle defined above.

[0150] Measuring the number of times an animal scratches itself is an index of the presence of itch, defined as the scratch count in FIG.

[0151] As can be seen in Figure 3, treatment with imiquimod (5%) induces a significant increase in the number of scratches relative to animals treated with a control cream. Treatment with an antisense oligonucleotide complementary to the central portion of the mouse miR-203b-3p microRNA (shown as "CORE Seq Inhibitor" in Figure 3) was able to reduce the number of scratches at the site where the imiquimod (5%) cream was applied in mice treated with imiquimod (5%) (psoriasis model mice).

[0152] This experiment shows that an oligonucleotide with a sequence perfectly complementary to the central part of the mouse miR-203b-3p microRNA can reduce itch in a mouse model of psoriasis induced by imiquimod (5%).

[0153] Data are presented as mean±SEM. * p<0.05 vs. imiquimod vehicle (control); § p<0.05 vs. Imiquimod / CORE Seq inhibitor vehicle. Statistical analysis by one-way analysis of variance (ANOVA) and Bonferroni test.

Claims

1. 1. An antisense oligonucleotide for use in the treatment of psoriasis induced itch, complementary to the human miR-203b-3p microRNA (SEQ ID NO: 3), having the sequence (SEQ ID NO: 4) or a sequence having a percentage of identity to said sequence (SEQ ID NO: 4) equal to at least 70%, preferably at least 75%, more preferably at least 80%.

2. 2. The antisense oligonucleotide for use according to claim 1, comprising the eight nucleotide central sequence 5'-UUCUUAAC-3'.

3. 3. An antisense oligonucleotide for use according to claim 2, wherein the first uracil (U) of the central sequence UUCUUAAC corresponds to the base of the 9th nucleotide in an oligonucleotide for use according to the present invention, and the last cytosine (C) of the central sequence corresponds to the base of the 16th nucleotide in an oligonucleotide for use according to the present invention.

4. 4. An antisense oligonucleotide for use according to claim 2 or 3, wherein the central sequence 5'-UUCUUAAC-3' in said sequence (SEQ ID NO: 4) binds to the central portion 5'-GUUAAGAA-3' of said sequence (SEQ ID NO: 3) of human miR-203b-3p microRNA.

5. The antisense oligonucleotide for use according to any one of claims 1 to 4, which is in the antagomir form of the human miR-203b-3p microRNA (SEQ ID NO: 3).

6. The antisense oligonucleotide having a percentage of identity at least equal to 70% to the sequence (SEQ ID NO: 4) has the following sequence: 5'-ACA ACU UGU UCUUAA CAU GUC CA-3' (SEQ ID NO: 5) 5'-UCA CGU ACU UCUUAA CAU UUA CA-3' (SEQ ID NO: 6) 5'-AUG ACU GGU UCUUAA CAG UAG UA-3' (SEQ ID NO: 7) 5'-AGC UCA GGU UCUUAA CAG UUC AA-3' (SEQ ID NO: 8) 5'-UUA AGU GGU UCUUAA CAG CUA CA-3' (SEQ ID NO: 9) 5'-UGC UGA GGU UCUUAA CAG ACC AA-3' (SEQ ID NO: 10) 5'-UCA AAC GGU UCUUAA CAG UUC AA-3' (SEQ ID NO:11) 5'-UCC CGU GGU UCUUAA CAG CUC GA-3' (SEQ ID NO: 12) 5'-UGC AGC GGU UCUUAA CAG UUA AA-3' (SEQ ID NO: 13) 2. The antisense oligonucleotide for use according to claim 1, selected from the group comprising:

7. The antisense oligonucleotide for use according to any one of claims 1 to 6, wherein the psoriasis is selected from plaque psoriasis, pustular psoriasis, guttate psoriasis, inverse psoriasis and erythrodermic psoriasis.

8. The antisense oligonucleotide for use according to claim 7, wherein the psoriasis is plaque psoriasis.

9. A phospholipid vesicle comprising at least an antisense oligonucleotide as defined in any one of claims 1 to 6.

10. The phospholipid vesicle of claim 9, comprising at least an oligonucleotide selected from the group of oligonucleotides having the sequences (SEQ ID NO:5), (SEQ ID NO:6), (SEQ ID NO:7), (SEQ ID NO:8), (SEQ ID NO:9), (SEQ ID NO:10), (SEQ ID NO:11), (SEQ ID NO:12) and (SEQ ID NO:13).

11. 10. A phospholipid vesicle as described in claim 9, comprising an oligonucleotide having the sequence (SEQ ID NO:4) and at least a further oligonucleotide selected from the group of oligonucleotides having the sequences (SEQ ID NO:5), (SEQ ID NO:6), (SEQ ID NO:7), (SEQ ID NO:8), (SEQ ID NO:9), (SEQ ID NO:10), (SEQ ID NO:11), (SEQ ID NO:12) and (SEQ ID NO:13).

12. A phospholipid vesicle according to any one of claims 9 to 11, selected from liposomes, phytosomes, micelles or mixtures thereof.

13. A phospholipid vesicle according to claim 12 in the form of a liposome.

14. Phospholipid vesicles according to any one of claims 9 to 13 for use in the treatment of itch induced by plaque psoriasis, pustular psoriasis, guttate psoriasis, inverse psoriasis and erythrodermic psoriasis.

15. The phospholipid vesicle of claim 14, wherein the psoriasis is plaque psoriasis.

16. A pharmaceutical composition comprising at least the phospholipid vesicles according to any one of claims 9 to 15 and one or more pharma- ceutically suitable or pharma-ceutically acceptable excipients.

17. 17. The pharmaceutical composition of claim 16 in the form of a cream, powder, or ointment.

18. 18. The pharmaceutical composition according to claim 17 in the form of a cream for topical use.

19. A pharmaceutical composition according to any one of claims 16 to 18 for application by medicinal patch.

20. A pharmaceutical composition according to any one of claims 16 to 19 for use in the treatment of itch induced by plaque psoriasis, pustular psoriasis, guttate psoriasis, inverse psoriasis and erythrodermic psoriasis.

21. 21. The pharmaceutical composition of claim 20, wherein the psoriasis is plaque psoriasis.

22. A method of treatment of psoriasis induced itch comprising topical application of a therapeutically effective amount of a pharmaceutical composition according to any one of claims 16 to 19 to at least one psoriatic lesion of a subject suffering from psoriasis.

23. 23. The method of treatment of claim 22, further comprising administration of at least one drug for the treatment of psoriasis.

24. 24. The method of treatment of claim 23, wherein the at least one drug for the treatment of psoriasis is selected from corticosteroids, topical vitamin D3 analogues, calcineurin inhibitors and / or tazarotene.

25. Method of treatment according to claims 23 or 24, wherein said at least one drug for the treatment of psoriasis is administered before, after or simultaneously with the topical treatment with a pharmaceutical composition as defined in claims 16 to 19.